Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients

Abstract

Objective:

To determine the efficacy, safety and tolerability of cetilistat (ATL-962), a novel inhibitor of gastrointestinal (GI) lipases, in obese patients.

Design:

Phase II, multicentre, randomized, placebo-controlled, parallel group study. Enrolled patients (N=442) were advised a hypocaloric diet (deficient by 500 kcal per day, 30% of calories from fat) for a 2-week run-in period. Patients who satisfied the entry criteria (N=371) continued on the hypocaloric diet and were randomized to either placebo or one of three different doses of cetilistat (60 mg three times daily t.i.d., 120 mg t.i.d. and 240 mg t.i.d.) for 12 weeks, followed by a 4-week post-treatment follow-up. Safety, tolerability and body weight were assessed, together with other parameters associated with obesity.

Outcome measures:

The primary outcome measure was absolute change in body weight from baseline. Secondary outcomes included the proportion of patients achieving pre-defined weight loss targets, changes from baseline in waist circumference and in blood lipids. GI tolerability criteria were specifically assessed, as was safety.

Results:

Treatment with cetilistat reduced mean body weight to similar extents at all doses, which were statistically significant compared with placebo (60 mg t.i.d. 3.3 kg, P<0.03; 120 mg t.i.d. 3.5 kg, P=0.02; 240 mg t.i.d. 4.1 kg, P<0.001). Total serum and low-density lipoprotein cholesterol levels were likewise significantly reduced by 3–11% at all doses of cetilistat. Cetilistat was well tolerated. The frequency of withdrawal owing to treatment-emergent adverse events was similar between cetilistat-treated groups (5.3–7.6%) and placebo (7.6%). Adverse events were generally mild to moderate in intensity, occurred on only one occasion and were mostly GI in nature. The incidence of GI adverse events was increased in the cetilistat-treated groups compared to placebo. However, those GI adverse events, such as flatus with discharge and oily spotting, only occurred in 1.8–2.8% of subjects in the cetilistat-treated groups.

Conclusions:

Cetilistat produced a clinically and statistically significant weight loss in obese patients in this short-term 12-week study. This was accompanied by significant improvements in other obesity-related parameters. Cetilistat treatment was well tolerated. The risk–benefit demonstrated in this study in terms of weight loss vs intolerable GI adverse effects shows that cetilistat merits further evaluation for the pharmacotherapy of obesity and related disorders.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000; 894: i–xii, 1–253.

  2. Hubert HB, Feinleib M, McNamara PM, Castelli WP . Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983; 67: 968–977.

    Article  CAS  Google Scholar 

  3. MacMahon S, Cutler J, Brittain E, Higgins M . Obesity and hypertension: epidemiological and clinical issues. Eur Heart J 1987; 8 (Suppl B): 57–70.

    Article  Google Scholar 

  4. Blackburn G . Effect of degree of weight loss on health benefits. Obes Res 1995; 3 (Suppl 2): 211s–216s.

    Article  Google Scholar 

  5. Vidal J . Updated review on the benefits of weight loss. Int J Obes Relat Metab Disord 2002; 26 (Suppl 4): S25–S28.

    Article  Google Scholar 

  6. Mertens IL, Van Gaal LF . Overweight, obesity, and blood pressure: the effects of modest weight reduction. Obes Res 2000; 8: 270–278.

    Article  CAS  Google Scholar 

  7. Goldstein DJ . Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992; 16: 397–415.

    CAS  PubMed  Google Scholar 

  8. Finer N, James WP, Kopelman PG, Lean ME, Williams G . One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord 2000; 24: 306–313.

    Article  CAS  Google Scholar 

  9. Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352: 167–172.

    Article  Google Scholar 

  10. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281: 235–242.

    Article  CAS  Google Scholar 

  11. Dunk C, Enunwa M, De la Motte S, Palmer RMJ . Increased faecal fat excretion in normal volunteers treated with lipase inhibitor ATL-962. Int J Obes Relat Metab Disord 2002; 26 (Suppl 1): S1–S245.

    Google Scholar 

  12. Drent ML, Larsson I, William-Olsson T, Quaade F, Czubayko F, von Bergmann K et al. Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int J Obes Relat Metab Disord 1995; 19: 221–226.

    CAS  PubMed  Google Scholar 

  13. Van Gaal LF, Broom JI, Enzi G, Toplak H . Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group. Eur J Clin Pharmacol 1998; 54: 125–132.

    Article  CAS  Google Scholar 

  14. Hanotin C, Thomas F, Jones SP, Leutenegger E, Drouin P . Efficacy and tolerability of sibutramine in obese patients: a dose ranging study. Int J Obes Relat Metabol Disord 1998; 22: 32–38.

    Article  CAS  Google Scholar 

  15. Lean ME . Sibutramine – a review of clinical efficacy. Int J Obes Relat Metab Disord 1997; 21 (Suppl 1): 530–536 (discussion 37–39).

    Google Scholar 

  16. Jensen M, Abu-Lebdeh H, Geohas J, Brazg R, Block M, Noveck R et al. The selective CB1 receptor antagonist rimonabant reduces bodyweight and waste circumference in obese subjects. Int J Obes Relat Metab Disord 2004; 28 (Suppl 1): S27.

    Google Scholar 

  17. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S . Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389–1397.

    Article  CAS  Google Scholar 

  18. Wing RR, Koeske R, Epstein LH, Nowalk MP, Gooding W, Becker D . Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med 1987; 147: 1749–1753.

    Article  CAS  Google Scholar 

  19. Orzano AJ, Scott JG . Diagnosis and treatment of obesity in adults: an applied evidence-based review. J Am Board Fam Pract 2004; 17: 359–369.

    Article  Google Scholar 

  20. Zimmerman J, Kaufmann NA, Fainaru M, Eisenberg S, Oschry Y, Friedlander Y et al. Effect of weight loss in moderate obesity on plasma lipoprotein and apolipoprotein levels and on high density lipoprotein composition. Arteriosclerosis 1984; 4: 115–123.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was financially supported by Alizyme Therapeutics Ltd, Cambridge, UK. All of the authors were involved in the design and implementation of the study and in the preparation of this manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to P Kopelman.

Additional information

For more details regarding clinical investigators and their affiliations, see Appendix A.

Appendix A

Appendix A

Clinical investigators and their affiliations

S Toubro, Fredriksberg, Denmark; A Astrup, Hvidovre, Denmark; K Kølendorf, Frederiksberg, Denmark; B Richelsen, Aarhus, Denmark; A Rissanen, Helsinki, Finland; L Niskanen, Kuopio, Finland; P Valensi, Bondy, France; P Ritz, Angers, France; J-P Louvet, Toulouse, France; M Krempf, Nantes, France; S Rössner, Huddinge, Sweden; T Lindström, Linköping, Sweden; J Torgerson, Gothenburg, Sweden; A Hänni, Uppsala, Sweden; P Kopelman, Norwich, UK; S Bloom, London, UK; S Kumar, Birmingham, UK; M Lean, Glasgow, UK; N Finer, Luton, UK; I Broom, Aberdeen, UK.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kopelman, P., Bryson, A., Hickling, R. et al. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int J Obes 31, 494–499 (2007). https://doi.org/10.1038/sj.ijo.0803446

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijo.0803446

Keywords

Search

Quick links